Back
Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
Retina specialists come together to share key insights from multiple patient cases, highlighting how novel therapies like faricimab and aflibercept 8 mg have improved durability and patient outcomes in neovascular AMD, DME, and RVO.
Real-World Evidence on the Efficacy and Durability of Novel Therapies for nAMD, DME, and RVO
Episodes
All
All
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
3
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
4
Anti-Alpha-Gal Antibodies Block IgE Binding in Alpha-Gal Syndrome
5